Omeprazole/amoxicillin/rifabutin

Omeprazole/amoxicillin/rifabutin
Combination of
OmeprazoleProton-pump inhibitor
AmoxicillinPenicillin-class antibacterial
RifabutinRifamycin antibacterial
Clinical data
Trade namesTalicia
AHFS/Drugs.comProfessional Drug Facts
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Omeprazole/amoxicillin/rifabutin, sold under the brand name Talicia, is a fixed-dose combination medication used for the treatment of Helicobacter pylori infection.[1] It is taken by mouth.[1]

It was approved for medical use in the United States in November 2019.[2]

References

  1. 1 2 3 "Talicia- omeprazole magnesium, amoxicillin and rifabutin capsule, delayed release". DailyMed. Retrieved 4 October 2021.
  2. "Drug Approval Package: Talicia". U.S. Food and Drug Administration (FDA). 9 April 2020. Retrieved 4 October 2021.
  • "Omeprazole". Drug Information Portal. U.S. National Library of Medicine.
  • "Amoxicillin". Drug Information Portal. U.S. National Library of Medicine.
  • "Rifabutin". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT03198507 for "ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator (ERADICATE Hp2)" at ClinicalTrials.gov
  • Clinical trial number NCT01980095 for "ERADICATE Hp - Treating Helicobacter Pylori With RHB-105 (ERADICATE Hp)" at ClinicalTrials.gov


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.